Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025

Supplementary Figure S8 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Inhibition of CXCR2 enhances efficacy of myeloid Trem2 and anti-PD-1 treatment in NASH-driven HCC, suggesting a novel approach.

Key Points

  • Inhibiting CXCR2 enhances the effectiveness of targeting myeloid Trem2 and anti-PD-1 treatment in NASH-driven HCC.
  • Combining Trem2 targeting with anti-PD-1 shows improved treatment responses in hepatocellular carcinoma associated with NASH.
  • Targeting myeloid Trem2 plus CXCR2 inhibition represents a promising strategy for enhancing checkpoint immunotherapy outcomes.
  • This approach may lead to significant advancements in the treatment of NASH-related liver cancer.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a219e8https://doi.org/10.1158/2326-6066.30255472
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S1 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  2. 2Supplementary Figure S2 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  3. 3Supplementary Figure S7 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  4. 4Supplementary Figure S3 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025
  5. 5Supplementary Figure S4 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis2025